Skip to content

Comparative Study 27G Vitrectomy vs Larger Gauge Surgery

Comparative Study 27G Vitrectomy vs Larger Gauge Surgery

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04412525
Enrollment
50
Registered
2020-06-02
Start date
2020-06-05
Completion date
2021-01-23
Last updated
2022-07-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Vitreoretinal Surgery

Brief summary

Two-arm, mono-center, prospective, interventional comparative case study to compare postoperative recovery between the 27G and larger gauge surgical approach.

Detailed description

A prospective randomized comparison of postoperative recovery between 27-gauge and larger gauge surgical approaches to evaluate efficiencies and postoperative outcomes of the surgical gauges. Fifty patients who were scheduled to undergo pars plana vitrectomy (PPV) for floaters or macular surgery were treated with either 27-gauge or 23-gauge techniques and assessed for efficiency of the procedures as well as a variety of postop indicators of pain and inflammation.

Interventions

DEVICEvitrectomy (27G gauge or larger needle)

vitrectomy surgery for either floater removal or macular surgery, with or without combined cataract (phaco) surgery.

Sponsors

Universitaire Ziekenhuizen KU Leuven
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Subject)

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Patients aged over 18 * No prior vitrectomy surgery in the study eye (for the same eye) * No prior inclusion in this trial * Scheduled for vitrectomy for floater removal or macular surgery (including macular holes) without endotamponades such as PFCL, Gas, Silicone oil). (Air tamponade is allowed )

Exclusion criteria

* • Patients with serious heart, lung, liver, or kidney dysfunction * Patients with proliferative diabetic retinopathy, endophthalmitis, uveitis, eyes with refraction \>+5D or exceeding -8D , or other eye disease that impacts the outcome of vitrectomy surgery * Patients with HIV * Patients with history of drug abuse or alcoholism * Patients participating in other drug or medical device clinical trials before screening for this trial

Design outcomes

Primary

MeasureTime frameDescription
changes in post-operative outcome of painday 1 postoperativeby assessing the amount of pain on a visual analogue scale (score 0-9)
changes in post-operative outcome of rednessday 1 postoperativescoring the amount of redness on a scale 0-4 through eye photos
changes in post-operative outcome in grading of anterior chamber cellsday 1 postoperativeclinical assessment by slit lamp examination (Tyndall 0-3 and Cells 0-3)

Secondary

MeasureTime frameDescription
visual acuityday 1 postoperativebest corrected visual acuity in LogMar will be obtained to report the visual acuity
intra-ocular pressureday 1 postoperativeMillimeter of Mercury pressure (mmHg) will be measured to report the intra-ocular pressure
pain-assessment1 week postoperativea questionnaire with visual analogue scale will be used to assess the level of pain up to 1 week after the operation

Countries

Belgium

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026